Boehringer Ingelheim and Veeva (VEEV) Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Veeva Systems’ Earnings Call Highlights Strong Growth and Strategic Wins
- Veeva price target raised to $245 from $240 at Scotiabank
- Veeva price target raised to $217 from $210 at Truist
- Veeva price target lowered to $285 from $300 at Raymond James
Questions or Comments about the article? Write to editor@tipranks.com